Custom Products & Services
In addition to Synvolux’ products for the transfection of DNA, RNA and proteins, Synvolux also offers several custom products and services. SAINT-Vivo has been developed as an efficient in vivo delivery agent for DNA vaccines that have been shown to elicit potent T and B cell responses. Customers may also provide targeting reagents (e.g. antibodies) and cargo (e.g. siRNA) for the production of custom liposomes (SAINT-O-Somes) for in vitro and in vivo applications. If you are looking for GMP-compliant transfection reagents, please contact us. Click the relevant tabs below for more information on these custom products and services.
For clients with difficult-to-transfect cells or not enough time or resources on their hand, Synvolux also offers custom screening and optimization services to identify the most suitable transfection reagent from Synvolux’ library of >100 distinct transfection reagents in combination with DNA, siRNA, mRNA, or protein/peptides. Feel free to contact us to discuss your needs and wishes.
In vivo transfection reagent
SAINT-Vivo
SAINT-Vivo enables in vivo transfection and vaccination
SAINT-Vivo is an optimised version of the SAINT-18 cationic lipid, which has been used by several groups of researchers for in vivo application as a delivery agent for DNA.
The group of C.N.Kuo et al. has shown non-inflammatory corneal transfection in rats. In one of their publications they demonstrate inhibition of corneal neovascularization with a plasmid encoding pigment epithelium-derived factor (p-PEDF), delivered by SAINT-18, in an experimental model of rat corneal angiogenesis. Yet another publication examines the combination of a recombinant humanized monoclonal antibody to VEGF with p-PEDF/SAINT-18. Together, this work demonstrates that a combination of antibody and gene therapy using SAINT-18 may have potent and prolonged anti-angiogenic effects, thus providing a potential new therapy for severe complications of ischaemic ocular diseases caused by neovascularisation.
In the field of DNA vaccination, Endmann et al. have shown SAINT-mediated delivery of a gene expression vector coding for hepatitis B virus surface antigen (HBsAg). Upon intradermal injection of this DNA vaccine, a dose-dependent antibody response was elicited in mice. Another publication by the same group demonstrated that when administered in combination with SAINT-18, the expression vector is found in significantly larger amounts in draining lymph nodes compared to the same vector without SAINT-18. Furthermore, the use of SAINT-18 resulted in greater antigen expression, and the combination of SAINT-18 with the gene expression vector was well tolerated in mice and rats. In a study in pigs, Endmann et al. show that a SAINT-18 formulated DNA vaccine at a relatively low dose elicits an immune response similar to a normal dose of a commercial, licensed aluminum hydroxide-adjuvanted protein vaccine. After three vaccinations, the SAINT-18 formulated DNA vaccine induces a specific antibody response at a level considered protective. In conclusion, a SAINT-formulated DNA vaccine may provide a safe and effective alternative to current hepatitis B vaccines.
A research group at the university of Hannover has shown the application of SAINT-18 as a delivery agent in therapeutic DNA vaccination therapy against equine melanoma. Grey horses vaccinated thrice with DNA vectors encoding equine IL-12 and IL-18 display a significant decrease in tumour burden.
In conclusion, these animal studies demonstrate that SAINT-18 is an excellent delivery vehicle for gene expression vectors for in vivo applications, including DNA vaccines that elicit effective immune responses against viruses and cancer.
For Research Use Only. Not for use in diagnostic procedures.